Professional Documents
Culture Documents
Data Integrity: FDA/EMA Requirements and Implementation
Data Integrity: FDA/EMA Requirements and Implementation
SPEAKER
David L. Chesney, Principal and General Manager, DL Chesney Consulting, LLC (Former FDA Director)
His career includes 23 years with the FDA and over 21 years in GMP and In 1991, he was appointed the District Director, FDA San Francisco District Office, where
GCP consulting worldwide. In his consulting practice, Mr. Chesney helps he served until joining PAREXEL in 1995. For 19 years, he led the Strategic Compliance
clients prevent quality and compliance problems through proactive Consulting group, and also personally provided regulatory enforcement related consulting
assessment and planning, and when necessary, with remediation services to the pharmaceutical, medical device and biologics industries, plus technical
planning and health regulatory authority communications. assistance to legal counsel in FDA regulatory matters. Mr. Chesney has a bachelor's
degree and postgraduate credits in biology from California State University, Northridge
Until recently, he served as Vice President, Strategic Compliance and San Diego, and received a Certificate in Health Care Compliance from Seton Hall
Services for PAREXEL Consulting, a business unit of PAREXEL University School of Law.
International LLC. Prior to joining PAREXEL Consulting in 1995, Mr.
Chesney served 23 years with the FDA, where he advanced from
Investigator to Supervisory Investigator and Director, Investigations
Branch, working in the Boston, Seattle and Philadelphia District Offices.
LEARNING OBJECTIVES
Upon completing this course participants should:
Understand the meaning of the term “data integrity” and the importance of the acronym “A.L.C.O.A.” to regulatory agencies
Understand the difference between innocent lapses and deliberate wrongful conduct
Be aware of some of the key historical events that form the basis for regulators’ concerns about data integrity
Understand some of the common motivations for deliberate wrongful conduct that results in data falsification
Understand the impact of the use of computer systems on the maintenance of data integrity, and what types of system controls are mandated by various agencies
around the world
Be aware of the possible business and regulatory consequences of noncompliance
Understand the important steps to take to prevent, detect and react to data integrity problems
www.complianceonline.com
6201 America Center Drive, Suite 240 San Jose, CA 95002 | Fax: 650-362-2367 | Email: customercare@complianceonline.com | Toll Free: +1-888-717-2436
2-Day Virtual Seminar by Ex-FDA Director
02
DATA INTEGRITY: FDA/EMA/TGA REQUIREMENTS AND IMPLEMENTATION
COURSE DESCRIPTION
The integrity of data generated in support of marketing authorizations and in GMP, GCP The use of computer systems in virtually every aspect of data acquisition, storage, and
and GLP regulated activities is foundational to sound decision making and regulatory analysis can help preserve data integrity and reduce or eliminate many errors, but the
compliance. Data integrity lapses are among the most serious concerns that same technology can also create unique problems that must be prevented and managed.
pharmaceutical regulatory authorities have. Enforcement penalties can be severe from a
business standpoint, and in extreme cases can even impact individuals who are held In this two day workshop conference you will learn the meaning of "data integrity"; be
responsible for the occurrence of data integrity problems. In recent months the topic of exposed to some of the history that influences current regulatory requirements and
data integrity has been in the forefront of concern among worldwide pharmaceutical expectations; see a comparison of the current guidance from leading regulatory agencies
regulatory agencies. The FDA, EMA, TGA and others have published guidelines setting including the FDA, EMA, TGA and key industry associations such as the Parenteral Drug
forth their requirements and expectations for the maintenance of data integrity, as has at Association; see a recap of the enforcement options available to the FDA, including
least one leading industry organization (PDA). imposition of the Application Integrity Policy (also known as the "Fraud Policy"); discuss
and learn from selected current real-life case histories; and hear advice for how to prevent,
detect and react to data integrity problems so as to minimize business and regulatory risk.
AGENDA
Day One (11:00 AM - 5:00 PM EDT) Day Two (11:00 AM - 5:00 PM EDT)
11.00 AM: Session Start Welcome and time for questions from day one
Introductions Comparison of current data integrity guidance documents from
Instructor regulators and industry sources
Participants FDA
Determination of participant’s desires and expectations for the session EMA
The American “Generic Drug Scandal” of the late 1980s- early 90s and Civil and criminal sanctions
Case study: Consent decree imposed on a company outside the US;
its consequences
Expansion of computer system use in GXP operations and its impact implications of extraterritorial jurisdiction asserted by FDA
Emergence of current worldwide concern among regulators EMA/MHRA
Other agencies
Motivators behind deliberate wrongful conduct
Business consequences – Case study examples
“Achieve gain”
“Avoid pain” Steps to take to prevent, detect and react to data integrity problems
Managing to avoid the “Law of Unintended Consequences” Fundamentals of good documentation practice
Retention of true copies in lieu of originals – is it allowed, and if so,
Computer system issues
what are the expectations?
Audit trails
Signs you may have a data integrity problem
Changes to data
How to react if you suspect deliberate falsification
Metadata implications for data integrity
Involving legal counsel and external expert assistance
Computer System Controls required by the US and EMA
Considerations for voluntary disclosure to regulators
FDA Case studies of data integrity issues
(with concurrence of legal counsel)
GMP
GCP Questions, general discussion, summary and wrap up
GLP
www.complianceonline.com
6201 America Center Drive, Suite 240 San Jose, CA 95002 | Fax: 650-362-2367 | Email: customercare@complianceonline.com | Toll Free: +1-888-717-2436
2-Day Virtual Seminar by Ex-FDA Director
DATA INTEGRITY: FDA/EMA/TGA REQUIREMENTS AND IMPLEMENTATION
Note: In view of Coronavirus situation and travel advisory issued, ComplianceOnline will waive off all cancellation charges for the registrations till
May 31, 2021
Attendee Details:
Organization ....................................................................................... Check enclosed, payable in U.S. funds to ComplianceOnline (MetricStream, Inc.)
www.complianceonline.com
6201 America Center Drive, Suite 240
San Jose, CA 95002
Ph: +1-888-717-2436 | Fax: +1-650-362-2367
www.complianceonline.com
6201 America Center Drive, Suite 240 San Jose, CA 95002 | Fax: 650-362-2367 | Email: customercare@complianceonline.com | Toll Free: +1-888-717-2436